1
|
Husson B, Lind S, Fossheim M, Kato‐Solvang H, Skern‐Mauritzen M, Pécuchet L, Ingvaldsen RB, Dolgov AV, Primicerio R. Successive extreme climatic events lead to immediate, large-scale, and diverse responses from fish in the Arctic. GLOBAL CHANGE BIOLOGY 2022; 28:3728-3744. [PMID: 35253321 PMCID: PMC9321067 DOI: 10.1111/gcb.16153] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 01/17/2022] [Indexed: 06/14/2023]
Abstract
The warming trend of the Arctic is punctuated by several record-breaking warm years with very low sea ice concentrations. The nature and reversibility of marine ecosystem responses to these multiple extreme climatic events (ECEs) are poorly understood. Here, we investigate the ecological signatures of three successive bottom temperature maxima concomitant with surface ECEs between 2004 and 2017 in the Barents Sea across spatial and organizational scales. We observed community-level redistributions of fish concurrent with ECEs at the scale of the whole Barents Sea. Three groups, characterized by different sets of traits describing their capacity to cope with short-term perturbations, reacted with different timing and intensity to each ECE. Arctic species co-occurred more frequently with large predators and incoming boreal taxa during ECEs, potentially affecting food web structures and functional diversity, accelerating the impacts of long-term climate change. On the species level, responses were highly diversified, with different ECEs impacting different species, and species responses (expansion, geographical shift) varying from one ECE to another, despite the environmental perturbations being similar. Past ECEs impacts, with potential legacy effects, lagged responses, thresholds, and interactions with the underlying warming pressure, could constantly set up new initial conditions that drive the unique ecological signature of each ECE. These results highlight the complexity of ecological reactions to multiple ECEs and give prominence to several sources of process uncertainty in the predictions of climate change impact and risk for ecosystem management. Long-term monitoring and studies to characterize the vertical extent of each ECE are necessary to statistically link demersal species and environmental spatial-temporal patterns. In the future, regular monitoring will be crucial to detect early signals of change and understand the determinism of ECEs, but we need to adapt our models and management to better integrate risk and stochasticity from the complex impacts of global change.
Collapse
|
2
|
Lind S, Gatti P, Kristjansdottir I, Gadler F. Prevalence of left bundle branch block and CRT treatment in a large regional unselected ECG database. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Heart failure is a clinical syndrome in which signs and symptoms are due to functional and/or structural abnormalities of the heart which prevent the necessary supply of oxygenated blood or do so at the expense of high filling pressures. It has a prevalence of 1–2% in the western world and increasing prevalence with increasing age. While the prognosis for coronary heart disease has improved significantly, the same does not apply for heart failure, perhaps because some effective treatment methods have not been sufficiently implemented in health care. One effective but underutilized heart failure treatment is the cardiac resynchronisation therapy (CRT), that coordinates the contraction of the left and right ventricles via a pacemaker (PM). CRT treatment is an evidence based treatment recommended by among other the ESC guidelines for heart failure. Clinical studies have suggested decreases in mortality, hospitalization, morbidity and improvements in quality of life for heart failure patients receiving a CRT.
Purpose
To find a new clinical pathway to improve CRT implementation and to evaluate if it might be optimized through ECG-based surveillance and thus improving prognosis.
Methods
In a population of approximately 2.5 million people in our region we investigated the University Hospital's ECG database between 2000 and 2018. During which time 432 108 adult patients with 1 482 489 ECG's presented to the hospital. We searched and found 5 511 unique patients with the following ECG criteria: QRS ≥150 ms at any time, LBBB and Non pace. According to the Pacemaker Registry we excluded 771 patients that had previously received a PM/CRT. We also identified patients with diagnosis of heart failure by using the ICD-10 codes (I42.0 and I50).
Results
Our final cohort consists of 4 740 patients. The median age was 75 (19–112) years, 34.5% were female and 14.9% were subsequently implanted with a CRT (60% with CRT-D). The median time to CRT implantation from the first ECG with LBBB was 244 (IQR 994) days. Of the 4 740 patients 20.6% had a previous hospitalistion for heart failure with a median delay from the hospitalisation to CRT implantation of 5 (IQR 5.4) years.
Conclusions
Our observational data from a large real-life regional ECG database show there is a considerable number of heart failure patients that could benefit from CRT treatment. Using an existing ECG database could be useful in finding patients with indication for CRT implantation. This could possibly influence morbidity and mortality in a regional heart failure population by minimizing the delay of CRT treatment.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Karolinska University Hospital Research Fund
Collapse
|
3
|
O'Gorman C, Khoury R, Anderson A, Carter M, DiCesare F, Dubé S, Ereshefsky L, Grossberg G, Hefting N, Khan S, Lind S, Moebius H, Shiovitz T, Rosenberg P. A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE 2021; 7:274-282. [PMID: 32920630 DOI: 10.14283/jpad.2020.37] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Dementia is characterized by a significant decline in one of several cognitive domains such as memory, language and executive function, affecting independence and representing a significant deterioration from a previous level of functioning (1). Alzheimer’s Disease (AD) represents the most common form of dementia and contributes up to 70% of the almost 50 million dementia cases worldwide, a number that is projected to double in 20 years (2).
Collapse
|
4
|
Frainer A, Primicerio R, Dolgov A, Fossheim M, Johannesen E, Lind S, Aschan M. Increased functional diversity warns of ecological transition in the Arctic. Proc Biol Sci 2021; 288:20210054. [PMID: 33823664 PMCID: PMC8059624 DOI: 10.1098/rspb.2021.0054] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
As temperatures rise, motile species start to redistribute to more suitable areas, potentially affecting the persistence of several resident species and altering biodiversity and ecosystem functions. In the Barents Sea, a hotspot for global warming, marine fish from boreal regions have been increasingly found in the more exclusive Arctic region. Here, we show that this shift in species distribution is increasing species richness and evenness, and even more so, the functional diversity of the Arctic. Higher diversity is often interpreted as being positive for ecosystem health and is a target for conservation. However, the increasing trend observed here may be transitory as the traits involved threaten Arctic species via predation and competition. If the pressure from global warming continues to rise, the ensuing loss of Arctic species will result in a reduction in functional diversity.
Collapse
|
5
|
Lind S, Wallin L, Brytting T, Fürst C, Sandberg J. Implementation of national palliative care guidelines in Swedish acute care hospitals: A qualitative content analysis of stakeholders’ perceptions. Health Policy 2017; 121:1194-1201. [DOI: 10.1016/j.healthpol.2017.09.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 09/11/2017] [Accepted: 09/14/2017] [Indexed: 12/25/2022]
|
6
|
Levitsky A, Kisten Y, Nordström P, Lind S, Vivar N, van Vollenhoven R. AB0490 Kaltenborn's Manual Mobilization Method for Pain Relief in RA Hand Joints: Clinical and Ultrasound Findings in a Pilot Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4576] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
7
|
Sjöström D, Buhl S, Baker M, Andersen K, Dinesen NH, Lind S, Valentin S, Behrens C, Brandhof V. PD-0356 DEVELOP AND IMPLEMENTING A CANCER TYPE SPECIFIC EDUCATIONAL PROGRAM FOR IMAGE MATCHING. Radiother Oncol 2012. [DOI: 10.1016/s0167-8140(12)70695-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
8
|
Lind S, Baker M, Ottosson W, Hviid N, Landgren H, Hatting U. 1507 poster THE PROFESSIONAL ROLL OF RADIOTHERAPISTS IN IMPLEMENTING GATING TECHNIQUE: RESPIRATORY DEEP INSPIRATION BREATH HOLD FOR RADIATION TREATMENT OF LEFT-SIDED BREAST CANCER PATIENTS. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71629-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Deng X, Liu B, Fan Z, Edgerton S, Lind S, Thor A. Selective Effects of Glucose, Insulin and Leptin by Molecular Breast Cancer Subtype. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-5154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Type II diabetes and obesity are important risk factors for post-menopausal luminal A (LA) and triple negative (TN) pre-menopausal breast cancers, particularly in African American (AA) and Hispanic women. Breast cancer patients with these chronic metabolic diseases also have a worse prognosis, independent of other factors. We have published that metformin inhibits cell growth (S phase arrest) and induces apoptosis, only in TN cell lines in vivo and in vitro. It is less active, growth inhibitory (G1 arrest) and does not induce apoptosis in other breast cancer cell subtypes (Cell Cycle, 2009).Methods: We investigated the effects of glucose as a mitogen at physiologic (5mM), metabolic syndrome (7mM) or diabetic levels (10mM), with or without insulin (100 ng/ml) or leptin (100 ng/ml) using cell lines representing all molecular subtypes of breast cancer. Metformin was then used in combination with the above, to determine whether it would block the mitogenic or signaling effects of supraphysiological glucose, insulin or leptin.Results: The LA (MCF-7) and 2 of 5 TN cell lines (derived from AA patients; HCC 1806 and MDA 468) showed the most cell growth in response to glucose >5mM (75% for MCF-7, 30-50% for AA TN lines). Three TN cell lines from Caucasians (MDA231, HCC1937, BT20), the HER2 (SKBR3) and luminal B (BT-474) cells showed less growth induction with glucose >5mM. In TN lines only, glucose associated mitogenesis was associated with increased EGFR, pEGFR, IGF1R, pIGF1R, AKT and pAKT and decreases in AMPK, pAMPK, p38, IRS2, and the cyclins D1, E and A in a dose dependent manner. Metformin abrogated glucose induced cell growth and the aforementioned protein expression/phosphorylation changes involving EGFR, IGF1R, and AKT, increased AMPK and pAMPK and induced a profound reduction in Cyclin D1 across all glucose concentrations in TN cell lines from AA women. It reduced but did not eliminate glucose associated mitogenesis in the TN cell lines from Caucasian patients. Metformin had a more variable effect on cell lines of other molecular subtypes grown under high glucose conditions. The 5 TN breast cancer cell lines were uniformly resistant to both leptin and insulin associated mitogenesis, across a wide range of glucose concentrations. In contrast, both leptin and insulin significantly promoted LA breast cancer cell growth. These effects were resistant to metformin treatment. Leptin and insulin had the least growth promoting effects on HER2 breast cancer cell lines, whereas they induced modest growth induction in LB cell lines.Conclusions: All TN cell lines showed significant mitogenesis in response to glucose >5mM, whereas they were uniformly resistant to both leptin and insulin. The glucose associated mitogenesis was more pronounced in lines derived from AA patients, as were the anti-mitgenic effects of metformin. LA cells showed marked growth induction by glucose, leptin and insulin, whereas HER2 cell lines showed general resistance to all of these factors. These data suggest that metabolic and hormonal shifts with obesity and diabetes, as well as metformin response vary by the molecular subtype of breast cancer cells and ethnicity.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 5154.
Collapse
|
10
|
Thor A, Fan Z, Yang X, Esteva F, Jones F, Edgerton S, Lind S, Liu B. Metformin Enhances Trastuzumab Efficacy and Overcomes Resistance in HER2 Type Breast Cancer Cells. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1133] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: HER2 alterations occur in one-fourth of breast cancers and are associated with an aggressive tumor phenotype. The anti-HER2 agent trastuzumab reduces cell proliferation, angiogenesis, DNA repair and induces antibody-dependent cellular cytotoxicity. Objective response rates and median duration of response for eligible patients given trastuzumab alone is low (12-34% and 9 months respectively), hence, it is administered in combination with other agents. Mechanisms of trastuzumab resistance include: altered receptor antibody interactions, increased signaling through other EGFR type I growth factor receptors, modulation of p27 kip1 and increased insulin-like growth factor 1 receptor (IGF-1) signaling. We have reported that metformin inhibits HER2 expression, tyrosine kinase activity (phosphorylated HER2 at both auto- and Src- phosphorylation sites), AKT/mTOR signaling, Cyclin D1 and E2F1 with G1 arrest in HER2 overexpressing breast cancer cells. We sought to determine if metformin would enhance trastuzumab associated cytotoxicity and modulate acquired resistance in vitro.Methods: We used trastuzumab sensitive (SKBR3, BT474) and resistant cell lines (BT-474/HR20, SKBR3/P2, MCF-7/713 and MCF-7/HER2Δ16) to study the effects of metformin, metformin + trastuzumab and trastuzumab alone. Assays included MTS for proliferation, clonogenicity studies, Western blots, and pull down experiments with Western blots.Results: Trastuzumab sensitive breast cancer cells were less sensitive to metformin alone, compared to trastuzumab resistant HER2 subtype breast cancer cell lines. Trastuzumab sensitive cells showed enhanced growth and clonogenicity inhibition when treated by both metformin and trastuzumab. At the molecular level, these bi-treated cells showed decreases in HER2/pHER2, erbB3/perbB3, and inactivation of AKT and MAPk signaling. Metformin as low as 20mM increased the efficacy of trastuzumab. All HER2 resistant cell lines showed higher levels of IGF1R and HER2/IGF1R complexes, as compared to sensitive parental lines. In these resistant lines Metformin decreased cell proliferation and clonogenicity, HER2/IGF1R complexes (identified through pull down experiments) and protein expression of HER2/pHER2, erbB3/perbB3, IGF1R/pIGF1R as well as downstream signaling via Akt and IGF1 pathways. Metformin overcame trastuzumab resistance as demonstrated by growth and clonogenicity assays.Conclusions: HER2 amplified trastuzumab resistant breast cancer cells showed greater sensitivity to metformin than sensitive parental lines. Metformin reversed trastuzumab resistance and decreased HER2:IGF1R complexes, HER2/pHER2 and IGF1R expression, whereas sensitive parental lines showed no complex formation. These preclinical data suggest a combination of metformin and trastuzumab may have clinical benefit, improving the efficacy and reducing the emergence of or reversing trastuzumab resistance in HER2 positive breast cancer patients.Herceptin graciously provided by Genentech
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1133.
Collapse
|
11
|
Lind S, Olsson AG, Eriksson M, Rudling M, Eggertsen G, Angelin B. Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment. J Intern Med 2004; 256:406-12. [PMID: 15485476 DOI: 10.1111/j.1365-2796.2004.01401.x] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND Severe hereditary hypercholesterolaemia is most frequently due to familial hypercholesterolaemia (FH), caused by mutations in the LDL receptor (LDLR) gene. However, a phenotype very similar to FH may also be caused by defects in other genes like the genes for apolipoprotein (apo) B-100 or autosomal recessive hypercholesterolaemia (ARH). SUBJECT An 8-year-old male of Lebanese origin was diagnosed with severe hypercholesterolaemia and extensive cutaneous and tendon xanthomas. Plasma LDL cholesterol before treatment was 17 mmol L(-1), whilst parents and both siblings had normal levels. DIAGNOSIS Degradation of (125)I-labelled LDL in blood lymphocytes was reduced, but not abolished. Sequencing analysis of the LDLR and apoB-100 genes were negative, whilst a splice acceptor mutation in intron 1 (IVS 1 -1G>C) was detected in the ARH gene. The patient was homozygous for the mutation, whilst the parents were heterozygous. These findings were in agreement with a diagnosis of ARH. TREATMENT AND CLINICAL COURSE Monthly LDL apheresis and atorvastatin 120 mg daily reduced LDL cholesterol preapheresis level to 4.8 mmol L(-1). When ezetimibe was given 10 mg day(-1) in combination with rosuvastatin 80 mg day(-1), LDL cholesterol was further lowered to 1.6 mmol L(-1), which made apheresis unnecessary. Cutaneous and tendon xanthomas disappeared completely and the intima-media thickness of the common carotid arteries decreased. At age 23 he developed a small myocardial infarction. CONCLUSION ARH should be considered in cases of severe hypercholesterolaemia with a pattern of recessive inheritance. Combination therapy with high-dose statin and ezetimibe seems to be the treatment of choice in ARH and may reduce or eliminate the need for LDL apheresis treatment.
Collapse
|
12
|
Rudling M, Lind S, Ericsson S, Olivecrona H, Eriksson M, Borgström B, Eggertsen G, Berglund L, Angelin B. W13.334 Growth hormone induces LDL clearance but not bile acid synthesis in humans. ATHEROSCLEROSIS SUPP 2004. [DOI: 10.1016/s1567-5688(04)90333-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
13
|
Lind S, Rystedt E, Eriksson M, Wiklund O, Angelin B, Eggertsen G. Genetic characterization of Swedish patients with familial hypercholesterolemia: a heterogeneous pattern of mutations in the LDL receptor gene. Atherosclerosis 2002; 163:399-407. [PMID: 12052488 DOI: 10.1016/s0021-9150(02)00038-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Familial hypercholesterolemia (FH) is an autosomal codominant disease, caused by mutations in the LDL receptor gene. To characterize the distribution of genetic aberrations in Swedish FH-patients fulfilling the clinical criteria of FH, we have investigated 150 unrelated Swedish patients for mutations in the LDL receptor gene and for the most common mutation causing familial ligand defective apo B-100 (FDB). Of the patients, 77 were recruited from Huddinge University Hospital in Stockholm and 73 from Sahlgren's University Hospital in Göteborg. Screening was carried out using SSCP and Southern blotting techniques, combined with DNA sequence analysis. In total, mutations regarded as cause for disease were identified in 55 patients (37%), representing 32 different types of mutations. In the LDL receptor gene we detected four nonsense mutations, 13 missense mutations, seven splice junction mutations, and four major rearrangements. In addition, two small deletions were identified and one base exchange in the promoter region. The most common mutation (apo B3500) causing FDB was found in three patients. The most frequent mutation was FH-Helsinki, reflecting the admixture of Finnish immigrants. We further identified 15 point mutations which were not considered to affect the function of the gene, and thus were regarded as polymorphic changes. This multitude of mutations reflects a heterogeneous genetic background in our series of Swedish FH-patients and differs from the situation in the other Scandinavian countries. Future studies should aim at characterizing the importance of other genes for the development of the FH phenotype.
Collapse
|
14
|
Lind S. [Care for the demented: the use of elements from their life experience]. PFLEGE ZEITSCHRIFT 2001; 54:106-8. [PMID: 11235474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|
15
|
Lind S, Rystedt E, Eriksson M, Angelin B, Wiklund O, Eggertsen G. Mutations in the LDR-receptor gene in Swedish patients with familial hypercholesterolemia. Atherosclerosis 2000. [DOI: 10.1016/s0021-9150(00)81372-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
16
|
Dunlop TJ, Deen C, Lind S, Voyle RJ, Prichard JG. Use of combined oral narcotic and benzodiazepine for control of pain associated with bone marrow examination. South Med J 1999; 92:477-80. [PMID: 10342892 DOI: 10.1097/00007611-199905000-00005] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
BACKGROUND Bone marrow aspirate and biopsy is universally recognized as being painful. Few descriptions of effective analgesia or premedication for this procedure exist. In this study, we assessed an oral narcotic and benzodiazepine combination in controlling pain associated with bone marrow examination. METHODS Twenty-four consecutive ambulatory, adult patients referred for bone marrow examination received oral medications 90 minutes before the scheduled procedure. Patients reported perceived pain, using both Likert numerical and "Faces Pain Rating Scale," immediately after bone marrow examination and within 1 week after the procedure. Physicians' and nurses' evaluations of patient tolerance and the patients' memories of the aspiration and biopsy were recorded. RESULTS Two thirds (66%) of the respondents reported none or only mild pain (3 or less on a scale of 1 to 10). Memory of the procedure was vague or nonexistent in approximately half of the patients. There were no complications of biopsies or premedication. CONCLUSIONS Premedication with oral narcotic and benzodiazepine is effective in preventing or lessening pain associated with bone marrow examination in adults. Premedication induces amnesia for some or most of the procedure in about half of the patients.
Collapse
|
17
|
Lind S, Eriksson M, Rystedt E, Wiklund O, Angelin B, Eggertsen G. Low frequency of the common Norwegian and Finnish LDL-receptor mutations in Swedish patients with familial hypercholesterolaemia. J Intern Med 1998; 244:19-25. [PMID: 9698020 DOI: 10.1046/j.1365-2796.1998.00309.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVE To evaluate the frequency of the common Finnish and Norwegian mutations in the low density lipoprotein (LDL) receptor gene in Swedish patients with familial hypercholesterolaemia (FH), and to start screening for other mutations in these patients. In contrast to the situation in Norway and Finland, where the frequency of common mutations causing the disease has been determined, very little about the mutation spectrum is known in Sweden. SETTINGS AND SUBJECTS In total, 182 unrelated Swedish patients fulfilling clinical criteria for FH were investigated. Of these, 112 were identified at Huddinge University Hospital in Stockholm, and 70 at Sahlgren's Hospital in Göteborg. They were screened by single-strand conformation polymorphism (SSCP) for mutations in exons 3, 4, 6 and 9 of the LDL-receptor gene and by polymerase chain reaction (PCR) for the most common FH mutations occurring in Finland. and the prevailing mutation causing familial defective apolipoprotein B-100 (FDB). RESULTS Mutations in the LDL receptor were identified in 25 of the 182 patients. Of these, 10 represented FH-Helsinki and one FH-North Karelia. Other mutations identified were FH-Svartor (four patients), FH-Elverum (one patient), FH-Padova (two patients), FH-Morocco (one patient) and FH-Algeria-1 (one patient). One patient was simultaneously positive for two mutations formerly described in Sweden: E256K (exon 6) and 1402T (exon 9). Another mutation caused replacement of one amino acid residue in exon 6 (C292Y). Two new mutations were found, both in exon 6: one nonsense mutation in the codon #275 for cysteine (FH-Huddinge, two patients), and one deletion of two base-pairs in the codon for leucine in position 254 (FH-Göteborg, one patient). The mutation for FDB was found in three patients. CONCLUSIONS The mutation pattern in Swedish FH patients differs considerably from that in Finland and Norway. The two new mutations discovered will probably cause serious functional disturbances in the LDL-receptor function. Thus far, no predominant mutation was seen in Swedish FH-patients.
Collapse
|
18
|
Lind S. Circulating T cell repertoire in multiple sclerosis. Immunol Lett 1997. [DOI: 10.1016/s0165-2478(97)88108-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
|
20
|
Gupta A, Lind S, Eklund A, Lennmarken C. The effects of midazolam and flumazenil on psychomotor function. J Clin Anesth 1997; 9:21-5. [PMID: 9051541 DOI: 10.1016/s0952-8180(96)00214-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
STUDY OBJECTIVE To determine the effects of midazolam and its antagonism with flumazenil on psychomotor function as assessed by the perceptive accuracy test (PAT) and choice reaction time (CRT). DESIGN Double-blind, cross-over, randomized, placebo-controlled study. SETTING Department of Anaesthesiology, University Hospital, Linköping, Sweden. SUBJECTS 11 healthy volunteers (6 females, 5 males, mean age 32 years). INTERVENTIONS Midazolam 0.1 mg/kg (Group MH), midazolam 0.035 mg/kg (Group ML), or placebo (Group PL) were injected intravenously (IV) in a cross-over design. Flumazenil 0.5 mg was injected after 60 minutes. Plasma concentrations of midazolam were measured at 3, 30, 60 and 75 minutes. MEASUREMENTS AND MAIN RESULTS Baseline values were first obtained on psychomotor tests including the PAT and CRT. These tests were then repeated 30 and 60 minutes after the IV injection of midazolam or placebo, and repeated 15 and 30 minutes following the injection of flumazenil. A dose-dependent effect of midazolam was seen on the PAT and CRT. Flumazenil completely reversed the psychomotor effects of midazolam in Group ML at 60 minutes but not in Group MH, and this action was clearly detected by the PAT. Psychomotor tests had returned to baseline values when the plasma concentration of midazolam was below 33 ng/ml. A marked inter-individual variation was seen on the PAT, CRT, and in the correlation between the plasma concentration and the results on the PAT. CONCLUSIONS There was a dose-dependent deterioration in psychomotor performance in subjects given midazolam. The PAT was sensitive in the detection of these residual effects, but a large inter-individual variation in the psychomotor effects of midazolam was evident that could be due to pharmacodynamic and pharmacokinetic variability between individuals. Flumazenil in a dose of 0.5 mg IV completely reversed the effects of low-dose, but not high-dose, midazolam.
Collapse
|
21
|
Rojas N, Freer E, Weintraub A, Ramirez M, Lind S, Moreno E. Immunochemical identification of Brucella abortus lipopolysaccharide epitopes. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1994; 1:206-13. [PMID: 7496947 PMCID: PMC368229 DOI: 10.1128/cdli.1.2.206-213.1994] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Sera from Brucella abortus-infected and -vaccinated bovines recognized four lipopolysaccharide (LPS) determinants: two in the O-polysaccharide (A and C), one in the core oligosaccharide from rough Brucella LPS (R), and one in lipid A (LA). From 46 different hybridomas secreting monoclonal antibodies (MAbs) against various LPS moieties, 9 different specificities were identified. Two epitopes, A and C/Y, were present in the O-polysaccharide. Two epitopes were found in the core oligosaccharide (R1 and R2) of rough Brucella LPS. MAbs against R1 and R2 epitopes reacted against LPS from different rough Brucella species; however, MAbs directed to the R2 epitope also reacted against enterobacterial LPS from deep rough mutants. Three epitopes (LA1, LA2, and LA3) were located in the lipid A backbone. Different sets of MAbs recognized two epitopes in the lipid A-associated outer membrane protein (LAOmp3-1 and LAOmp3-2). LPS preparations from smooth brucellae had small amounts of rough-type LPS. Although LPS from rough brucellae did not show smooth-type LPS in western blots (immunoblots), two hybridomas generated from mice immunized with rough B. abortus produced antibodies against smooth B. abortus LPS. Results are discussed in relation to the structure and function of B. abortus LPS and to previous findings on the epitopic density of the molecule.
Collapse
|
22
|
Axelsson M, Lind S. [The final time can be lived fully]. VARDFACKET 1993; 17:28. [PMID: 8140808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
|
23
|
Lind S, Lindberg AA. Epitope size, specificity and equilibrium constant for four monoclonal antibodies binding to the O:4 polysaccharide antigen of Salmonella serogroup B bacteria. Mol Immunol 1992; 29:1013-23. [PMID: 1378926 DOI: 10.1016/0161-5890(92)90141-j] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
One rat (MAST 83) and three mouse (MAST 107, 108 and 112) monoclonal antibodies (mAbs) directed against Salmonella serogroup BO lipopolysaccharide (LPS) were characterized and found to bind to the O:4 epitope but recognizing different surfaces of the polysaccharide chain. The epitopes were defined from the combined results of: (i) binding specificities in enzyme immuno assay (EIA) against chemically defined LPS and glycoconjugates; (ii) studies of affinity constants in Farr-assay for binding to oligosaccharides purified from LPS, or chemically synthesized; and (iii) knowledge of the conformation of the O-polysaccharide chain of Salmonella BO bacteria. Two of the antibodies, MAST 83 and 108, bound to the O:4 epitope when present in the terminal non-reducing end as well as an intrachain determinant of the O-polysaccharide, whereas MAST 107 and 112 bound only to the O:4 epitope when present as an intrachain determinant. The equilibrium constants (K values), determined for binding of the mAbs and a Fab-fragment isolated from one of them to a 125l-labelled tyramine-derivative of a Salmonella BO dodecasaccharide, were: 4.3 x 10(5) (MAST 83), 1.0 x 10(5) (MAST 107), 1.3 x 10(5) (MAST 107 Fab), 4.5 x 10(4) (MAST 108) and 1.9 x 10(5) l/mol (MAST 112). The results suggest that each epitope encompasses the O:4 specifying D-abequosyl residue together with different numbers of saccharides varying in size from di- to tetrasaccharides from the linear backbone chain. The antibodies also bind to different surfaces of the O-polysaccharide chain as suggested by its conformation.
Collapse
|
24
|
Lind S, Heeg S. [Environment for patients with dementia. New perspectives of disease-oriented care of demented patients in old age homes]. DEUTSCHE KRANKENPFLEGEZEITSCHRIFT 1990; 43:744-7. [PMID: 2121435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
25
|
Flaherty CF, Grigson PS, Lind S. Chlordiazepoxide and the moderation of the initial response to reward reduction. THE QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY. B, COMPARATIVE AND PHYSIOLOGICAL PSYCHOLOGY 1990; 42:87-105. [PMID: 2326496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The effectiveness of chlordiazepoxide (CDP) in reducing negative contrast on the first day after a shift from 32% to 4% sucrose was investigated in four experiments using rats. Previous studies indicated that CDP was effective on the second, but not on the first postshift day. In Experiments 1 and 1a, neither initial experience (3 or 10 days) with the eventual postshift 4% solution (i.e. 4%, then 32%, then 4%), nor initial experience with alternating 4% and 32% sucrose, led to a reliable contrast-reducing effect of CDP on the first shift day. Evidence from Experiments 2 and 3 suggested that a range of doses of CDP (3, 5, 10, and 15 mg/kg) did not have reliable effects on the first postshift day, although the two lower doses did reduce contrast on the second postshift day (the higher doses were not administered on Day 2). The evidence suggests that the relative ineffectiveness of CDP in moderating the initial response to reward reduction is not related to a problem of recognizing the difference between the postshift solution and the memory of the preshift solution. Alternative interpretations in which CDP's lack of effect on the initial occurrence of contrast is related to an initial stage of unconditioned frustration and/or exploratory behaviour are considered.
Collapse
|